Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 18/20 | 0.73 |
| ▸ | CNR2 | P34972 | 10/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5922327 | 0.88 | CNR1 (0.59) | CNR1CNR2 | |
| SCHEMBL5922301 | 0.86 | CNR1 (0.70) | CNR1CNR2 | |
| SCHEMBL5922332 | 0.86 | CNR1 (0.67) | CNR1CNR2 | |
| SCHEMBL4927754 | 0.85 | CNR1 (0.61) | CNR1CNR2 | |
| SCHEMBL14270595 | 0.85 | CNR1 (0.74) | CNR1CNR2 | |
| SCHEMBL3088290 | 0.85 | CNR1 (1.00) | CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL4241156 | 0.84 | CNR1 (0.98) | CNR1CNR2 | |
| SCHEMBL4241147 | 0.82 | CNR1 (0.94) | CNR1CNR2 | |
| SCHEMBL4919496 | 0.81 | CNR1 (0.74) | CNR1CNR2 | |
| SCHEMBL4918803 | 0.81 | CNR1 (0.60) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051433-A1 | Pyrrole-3-Carboxamide Derivatives for the Treatment of Obesity | ASTRAZENECA (SE) | 2008-02-28 | — | — | US | claimed |
| EP-1718610-A1 | PYRROLE-3-CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF OBESITY | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | claimed |
| WO-2005080328-A1 | PYRROLE-3-CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF OBESITY | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | claimed |
| US-20080051433-A1 | Pyrrole-3-Carboxamide Derivatives for the Treatment of Obesity | ASTRAZENECA (SE) | 2008-02-28 | — | — | US | disclosed |
| EP-1718610-A1 | PYRROLE-3-CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF OBESITY | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005080328-A1 | PYRROLE-3-CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF OBESITY | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051433-A1 | Pyrrole-3-Carboxamide Derivatives for the Treatment of Obesity | PC, GPR119, PGC | CNR1 143/4885CNR2 84/4885NPC1 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.